PHS
MDGL icon

PFM Health Sciences’s Madrigal Pharmaceuticals MDGL Stock Holding History

PFM Health Sciences’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.7M Sell
29,313
-4,833
-14% -$2.48M 1.35% 25
2026
Q1 		$17.9M Buy
34,146
+26,888
+370% +$12.8M 1.63% 18
2025
Q4 		$4.23M Buy
+7,258
New +$3.71M 0.42% 58
2024
Q3 		– Sell
-29,973
Closed -$8.4M – 82
2024
Q2 		$8.4M Hold
29,973
– – 0.42% 49
2024
Q1 		$8M Buy
+29,973
New +$7.06M 0.38% 57
2021
Q2 		– Sell
-82,534
Closed -$9.65M – 94
2021
Q1 		$9.65M Buy
+82,534
New +$9.62M 0.29% 66

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

PFM Health Sciences's MDGL Position: Q2 2026 in Review

PFM Health Sciences reduced its Madrigal Pharmaceuticals (MDGL) stake by 14% in Q2 2026, selling an estimated $2.48M and leaving 29,313 shares worth $15.7M. The position accounts for 1.35% of the portfolio, ranked #25.

PFM Health Sciences first reported a position in MDGL in Q1 2021 and has held it in 6 quarters since. The position peaked at $17.9M in Q1 2026. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

  • PFM Health Sciences held 29,313 shares of Madrigal Pharmaceuticals worth $15.7M as of Q2 2026.
  • PFM Health Sciences sold 4,833 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $2.48M.
  • Madrigal Pharmaceuticals made up 1.35% of PFM Health Sciences's portfolio in Q2 2026, its #25 holding.
  • PFM Health Sciences first reported a position in Madrigal Pharmaceuticals in Q1 2021 and has held it in 6 quarters since.
  • PFM Health Sciences's Madrigal Pharmaceuticals position peaked at $17.9M in Q1 2026.
  • 413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on PFM Health Sciences's 13F filing for Q2 2026, filed 14 Aug 2026.